#APLS

Christian Heneka

@christianheneka.bsky.social

2 weeks ago

Durfte bei @edufunkpodcast.bsky.social zu Gast sein 🫶🏻 Zu hören auf Spotify oder Apple Podcasts 🎙️🎧

#BlueLZ #Podcast #Musikunterricht #Digital #Bildung #iPad #APLS #GarageBand

Laura

@acplaura.bsky.social

2 months ago

2 x places available on APLS in Norfolk on the 22nd and 2rd January. #APLS

Gilbert Gerber

@giger1964.bsky.social

3 months ago

from
Compstatins: the dawn of clinical C3-targeted complement inhibition, by the Lambris lab, UPenn, 2022. (patents to Apellis)
www.sciencedirect.com/science/arti...
Fascinating read and even more fascinating prospects for the effector end, C5aR1 antagonists
#APLS #IFRX

Gilbert Gerber

@giger1964.bsky.social

3 months ago

"With several drug candidates targeting pathway-specific initiation (e.g., anti-C1s, anti-MASP2), amplification (e.g., FD and FB inhibitors) and effector functions (e.g., C5aR1 antagonists) in late-stage development, we finally enter a new era in complement-modulating therapies"
#IFRX #APLS

StockTitan

@stocktitan.net

3 months ago

The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN Apellis (Nasdaq: APLS) announced that NEJM published positive Phase 3 VALIANT results for EMPAVELI (pegcetacoplan) in C3 glomerulopathy (C3G) and primary IC-MPGN at Week 26.Key results: 68% proteinuria reduction versus placebo (p<0.0001); eGFR stabilization +6.3 mL/min/1.73 m2 versus placebo (nominal p=0.03); and 71% of treated patients achieved zero C3 staining. EMPAVELI showed a favorable safety profile consistent with prior experience and was FDA-approved July 28, 2025.

#APLS The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN

www.stocktitan.net/news/APLS/the-new-englan...

Zephyr Scalzetti

@zephsays.bsky.social

3 months ago

I’ll be live tweeting (skeeting?) the Alabama Public Library Service executive board meeting today.

We expect the board to approve new code changes that will ban positive depictions of trans people in youth sections of public libraries.

#APLS

StockTitan

@stocktitan.net

4 months ago

Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years Apellis (Nasdaq: APLS) reported five-year post hoc GALE data showing continuous treatment with SYFOVRE (pegcetacoplan) delayed geographic atrophy (GA) lesion growth by approximately 1.5 years versus sham/projected sham in patients with nonsubfoveal GA. Both monthly and every-other-month dosing regimens showed similar delay. The safety profile through five years remained consistent with prior reports. Detailed results will be presented at a future medical meeting.

#APLS Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years

www.stocktitan.net/news/APLS/apellis-announ...

InsiderFinance

@insiderfinance.com

4 months ago

🚨 Institutions #optionsvolume surge detected! AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM

🚨 Institutions #optionsvolume surge detected!

AM Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #FMC 13.6x
2. #OWL 8.2x
3. #BORR 4.0x
4. #APLS 3.5x
5. #IMSR 3.3x

#OptionFlow #OptionsTrading #Trading

InsiderFinance

@insiderfinance.com

4 months ago

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily averag

🎯 Momentum #Options Activity trade ideas! Heavy institutional #optionsvolume far above daily average with strong consensus on direction.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#FMC, #OWL, #BORR, #APLS, #GPRK

#OptionFlow #OptionsTrading #Trading

StockTitan

@stocktitan.net

4 months ago

Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results Generated $459 million in 3Q 2025 revenues, including $178 million in U.S. net product sales Received 152 new patient start forms for EMPAVELI ® (pegcetacoplan) in the first two months since launch in C3G and primary IC-MPGN Reported EMPAVELI U.S. net product revenue of $27 million, reflecting

#APLS Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results

www.stocktitan.net/news/APLS/apellis-pharma...

StockTitan

@stocktitan.net

4 months ago

New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week Apellis Pharmaceuticals (NASDAQ: APLS) announced new one-year Phase 3 VALIANT data for EMPAVELI (pegcetacoplan) in C3 glomerulopathy (C3G) and primary IC-MPGN presented at ASN Kidney Week on October 20, 2025. Key results: EMPAVELI sustained a 68% proteinuria reduction versus placebo (p<0.0001) at one year, with consistent effects irrespective of immunosuppressant use or baseline proteinuria. One-third of treated patients achieved complete proteinuria remission (UPCR ≤0.5 g/g) versus 3% on placebo at Week 26, maintained through one year. EMPAVELI stabilized eGFR and showed a safety profile consistent with prior data. Two anchored indirect treatment comparisons indicated EMPAVELI was superior to iptacopan on multiple proteinuria and composite renal endpoints, with noted methodological limitations for ITCs.

#APLS New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week

www.stocktitan.net/news/APLS/new-one-year-d...

StockTitan

@stocktitan.net

7 months ago

Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results Apellis Pharmaceuticals (Nasdaq: APLS) reported Q2 2025 financial results, highlighting significant achievements including FDA approval of EMPAVELI for C3G and IC-MPGN treatment. The company generated $178.5 million in total revenue, with SYFOVRE contributing $150.6 million in U.S. net product sales.Key developments include a $300 million royalty purchase agreement with Sobi for 90% of ex-U.S. EMPAVELI royalties and continued market leadership of SYFOVRE in GA treatment with 60% market share. The company reported a net loss of $42.2 million and cash position of $370 million, which combined with expected revenues and Sobi agreement funds, is anticipated to sustain operations until profitability.

#APLS Apellis Pharmaceuticals Reports Second Quarter 2025 Financial Results

www.stocktitan.net/news/APLS/apellis-pharma...

EarningsForesight

@earningsforesight.bsky.social

7 months ago

#JCI #MRK #NSC #PG #PYPL #RCL #SOFI #SPOT #CZR #EA #LOGI #QRVO #SBUX #STX #TER #V #VRNS #ADP #APLS #CHKP #ENTG #ETSY #EVR #FTV #FVRR #GIB #GNRC #GRMN #HOOD #KGC #LRCX #META #MGM #MSFT #NCLH #RBLX #AAPL #AMZN #IR #JNPR #KLAC #LUMN #MPS #MSTR #NET #OLED

StockTitan

@stocktitan.net

7 months ago

FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older Apellis Pharmaceuticals (Nasdaq: APLS) has received FDA approval for EMPAVELI® (pegcetacoplan) as the first treatment for C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) in patients 12 years and older.The approval is based on the Phase 3 VALIANT study results showing three key achievements: a 68% reduction in proteinuria (pThis breakthrough treatment targets rare kidney diseases affecting 5,000 people in the United States, where approximately 50% of patients progress to kidney failure within 5-10 years of diagnosis. The therapy demonstrated efficacy across both adolescent and adult patients, including those with post-transplant disease recurrence.

#APLS FDA Approves Apellis’ EMPAVELI® (pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older

www.stocktitan.net/news/APLS/fda-approves-a...

Timo Friedrich

@apfeledu.de

7 months ago

Digitale Unterrichtsplanung | Digitale Bildungswochen 2025 YouTube video by iPad Learning Community DACH

Digitale Bildungswochen 2025 verpasst? Dann gibt es jetzt die Möglichkeit, das Verpasste nachzuholen! 🙌 Hier findet Ihr meinen Workshop zur Digitalen Unterrichtsplanung als Teil der Playlist: youtube.com/watch?v=Oxk_... #dbw #digitalebildungswochen #appleprofessionallearning #apls

StockTitan

@stocktitan.net

8 months ago

Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting Apellis Pharmaceuticals (Nasdaq: APLS) announced that five abstracts highlighting SYFOVRE® (pegcetacoplan injection) data have been accepted for oral presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting from July 30 - August 2 in Long Beach, California.The presentations will showcase SYFOVRE's efficacy and safety profile in treating geographic atrophy (GA) secondary to age-related macular degeneration (AMD). The data demonstrates SYFOVRE's ability to slow GA progression with as few as six doses per year. The abstracts cover various aspects including baseline characteristics, early vs. delayed treatment results, clinical utility in bilateral GA, combination therapy with anti-VEGF treatments, and the impact of AREDS supplements on GA progression.SYFOVRE is notable as the first-ever approved therapy for GA, a condition affecting over one million Americans and five million people worldwide.

#APLS Apellis Announces Five Abstracts Accepted for Oral Presentation at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting

www.stocktitan.net/news/APLS/apellis-announ...

@andymaleh.bsky.social

8 months ago

JSON Response Strategies for Rails APls, Wed, Jul 16, 2025, 6:00 PM | Meetup **Event Timeline:** * **6:30pm - Pre-talk Networking Time - Anticafe Place Des Arts** (294 Saint-Catherine St W, 3rd floor, Montreal, Quebec H2X 2A1): this is a coworking

The July 2025 #Montreal.rb #Ruby #meetup #talk is going to be " #JSON Response Strategies for #Rails #APls " by Parham Ashraf, and will take place this Wednesday on July 16, 2025 at 6:30pm at Anticafe Place Des Arts (294 Saint-Catherine St W).

RSVP link: www.meetup.com/montrealrb/e...

#dev

Lianne Geddes

@lgeddesem.bsky.social

8 months ago

APLS in action
- enthusiastic faculty demonstrating to our candidates on day 2
#APLS #ALSG

@frimleyhealth.bsky.social
@resusgirl.bsky.social

StockTitan

@stocktitan.net

8 months ago

Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan) Apellis Pharmaceuticals (Nasdaq: APLS) has entered into a significant royalty purchase agreement with Sobi® worth up to $300 million for Aspaveli® (systemic pegcetacoplan). The deal includes $275 million upfront and potential $25 million in milestone payments tied to EMA approval for C3G and IC-MPGN indications.Under the agreement, Sobi will acquire 90% of Apellis' ex-U.S. royalties for Aspaveli, with royalty rates ranging from high teens to high twenties. Apellis maintains exclusive U.S. commercialization rights, where the product is marketed as EMPAVELI®. The agreement includes performance-based caps, after which all ex-U.S. royalties will revert to Apellis.Aspaveli/EMPAVELI is currently approved for paroxysmal nocturnal hemoglobinuria (PNH) treatment in the EU, U.S., and other countries. The drug is under regulatory review for C3 glomerulopathy (C3G) and IC-MPGN treatment, with an expected CHMP opinion before year-end and a PDUFA date of July 28, 2025.

#APLS Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)

www.stocktitan.net/news/APLS/apellis-to-rec...

Hannah

@hanspan1.bsky.social

8 months ago

Calling all APLS faculty... I have just completed my GIC course and need to join the faculty as an Instructor Canditate on 2 courses. I'm struggling to find courses with IC spaces - if you know if any, please get in touch.
#apls #paeds #paediatriclifesupport #paedrocks #alsg

StockTitan

@stocktitan.net

9 months ago

Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN Apellis Pharmaceuticals (APLS) and Sobi presented promising one-year data from the Phase 3 VALIANT study of EMPAVELI (pegcetacoplan) for treating C3G and primary IC-MPGN kidney diseases. The study demonstrated sustained efficacy with a significant 68% proteinuria reduction versus placebo at Week 26, maintained through one year. Patients showed stable kidney function measured by eGFR, with similar benefits observed in patients who switched from placebo to EMPAVELI. The drug maintained a favorable safety profile with no new safety signals. The data, presented at the ERA Congress, supports pending marketing applications under review with FDA and EMA, with an FDA decision expected this summer.

#APLS Apellis and Sobi Announce EMPAVELI® (pegcetacoplan) Showed Sustained Efficacy at One Year in Phase 3 Study for C3G and Primary IC-MPGN

www.stocktitan.net/news/APLS/apellis-and-so...

Sebastian Achatz

@mrachatz.bsky.social

10 months ago

#AugmentedReality im #Unterricht: Vom Herzmodell über einen Spaziergang am Mars bis zum T-Rex – erlebbares Lernen mit AR-Apps, #Storytelling mit #ARMakr und #RealityComposer.
#AR #DigitaleSchule #DigitaleBildung #KreativesLernen #AppleEDU #AppleProfessionalLearning #APLS #ADE #EDUSky #blueLZ

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

10 months ago

www.fool.com/investing/2025/05/07/why...

#APLS #^GSPC […]

[Original post on fool.com]

StockTitan

@stocktitan.net

10 months ago

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results Apellis Pharmaceuticals (APLS) reported Q1 2025 financial results with total revenue of $166.8 million, down from $172.3 million in Q1 2024. SYFOVRE U.S. net product sales were $130.2 million, with injection demand growing 4% QoQ despite revenue impacts from inventory dynamics and co-pay assistance program funding shortages. EMPAVELI generated $19.7 million in U.S. net product revenue. The company reported a net loss of $92.2 million, compared to $66.4 million in Q1 2024. With $358.4 million in cash as of March 31, 2025, Apellis expects combined cash and future sales to fund operations to profitability. The FDA accepted their sNDA for EMPAVELI with Priority Review for C3G and IC-MPGN treatment, with a decision expected in July 2025.

#APLS Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

www.stocktitan.net/news/APLS/apellis-pharma...

Profit Trading USA

@profittradingusa.bsky.social

10 months ago

Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts? - Yahoo Finance Is Apellis Pharmaceuticals, Inc. (APLS) Among the Best Guru Stocks to Buy According to Wall Street Analysts?  Yahoo Finance

Click Subscribe #ApellisPharmaceuticals #APLS #GuruStocks #WallStreet #Investing

Sebastian Achatz

@mrachatz.bsky.social

11 months ago

Danke an alle, die heute bei meiner Session im Rahmen der Digitalen Bildungswochen dabei waren! Es war mir eine große Freude, meine Erfahrungen mit euch zu teilen.
Ich hoffe, ihr konntet euch inspirieren lassen und ein paar Ideen mitnehmen. #bluelz #EduSky #AppleEduSky #APLS #ADE

Anathema Studio 🎮 🪄 🔭🔮✏️🌏 🌈 🌱 🫂 😈 🕷

@anathemastudio.bsky.social

11 months ago

Republicans cut a library's funding over LGBTQ+ books. Then the community did something surprising. - LGBTQ Nation Conservatives wanted to enforce an LGBTQ+ book ban at a local library, but local readers weren't having it.

#Republicans cut a library’s funding over #LGBTQ+ books

Then the community did something surprising

#Alabama #AL #APLS #GOP

www.lgbtqnation.com/2025/03/repu...